We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.49%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.36B
AUM Growth
-$287M
Cap. Flow
-$74.9M
Cap. Flow %
-0.8%
Top 10 Hldgs %
76.51%
Holding
102
New
8
Increased
20
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$42.6M
2
BCYC
Bicycle Therapeutics
BCYC
+$31.8M
3
GRAL
GRAIL Inc
GRAL
+$26.5M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$22M
5
RVMD icon
Revolution Medicines
RVMD
+$18.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$212M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$17.4M
3
TNGX icon
Tango Therapeutics
TNGX
+$5.78M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.31M
5
BMEA icon
Biomea Fusion
BMEA
+$5.24M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.5B
$2.12B 22.68%
30,739,466
+446
+0% +$31.8K
ONC
2
BeOne Medicines Ltd
ONC
$33.8B
$1.76B 18.81%
9,531,880
-1,037,017
-10% -$212M
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.43B
$787M 8.4%
42,877,916
– –
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.5B
$609M 6.51%
1,974,590
– –
SMMT icon
5
Summit Therapeutics
SMMT
$9.88B
$436M 4.66%
24,424,865
– –
RVMD icon
6
Revolution Medicines
RVMD
$38.2B
$347M 3.71%
7,936,972
+367,882
+5% +$18.6M
INSM icon
7
Insmed
INSM
$22.7B
$346M 3.69%
5,006,863
+590,945
+13% +$42.6M
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.3B
$341M 3.64%
6,084,249
-314,117
-5% -$17.4M
KYMR icon
9
Kymera Therapeutics
KYMR
$8.61B
$241M 2.58%
5,995,929
– –
KOD icon
10
Kodiak Sciences
KOD
$2.4B
$172M 1.84%
17,310,490
– –
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.28B
$164M 1.76%
6,155,940
+315,881
+5% +$10.1M
BCYC
12
Bicycle Therapeutics
BCYC
$269M
$152M 1.63%
10,885,357
+1,485,397
+16% +$31.8M
REPL icon
13
Replimune Group
REPL
$412M
$134M 1.43%
11,045,336
– –
ALKS icon
14
Alkermes
ALKS
$8.22B
$120M 1.28%
4,181,751
– –
TRDA icon
15
Entrada Therapeutics
TRDA
$229M
$84.1M 0.9%
4,865,819
– –
ABCL icon
16
AbCellera Biologics
ABCL
$1.62B
$80.7M 0.86%
27,525,640
– –
DNLI icon
17
Denali Therapeutics
DNLI
$3.76B
$76.1M 0.81%
3,731,695
– –
NRIX icon
18
Nurix Therapeutics
NRIX
$2.44B
$73.1M 0.78%
3,882,125
– –
ARGX icon
19
argenx
ARGX
$55.1B
$68.8M 0.74%
111,904
– –
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.51B
$66.3M 0.71%
1,576,114
– –
KNSA icon
21
Kiniksa Pharmaceuticals
KNSA
$6.14B
$55.7M 0.6%
2,818,323
– –
IMTX icon
22
Immatics
IMTX
$1.17B
$51.7M 0.55%
7,275,830
+832,432
+13% +$7.15M
CRSP icon
23
CRISPR Therapeutics
CRSP
$4.64B
$51.5M 0.55%
1,308,011
+464,936
+55% +$22M
STOK icon
24
Stoke Therapeutics
STOK
$1.81B
$51.1M 0.55%
4,633,838
+265,395
+6% +$3.26M
IMCR icon
25
Immunocore
IMCR
$1.68B
$44.7M 0.48%
1,515,318
– –
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Baker Bros. Advisors held 102 positions worth $9.36B, down 3% from $9.65B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors's Q4 2024 filing shows 8 new, 20 increased, 5 reduced and 7 closed positions. Its largest new stake was GRAIL Inc: 1,630,125 shares worth $29.1M. The largest sale was BeOne Medicines Ltd, an estimated $212M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2024 buy was GRAIL Inc: 1,630,125 shares worth $29.1M.
  • Baker Bros. Advisors added most to Insmed in Q4 2024, an estimated $42.6M increase.
  • Baker Bros. Advisors's biggest Q4 2024 reduction was BeOne Medicines Ltd, cutting an estimated $212M.
  • Baker Bros. Advisors fully exited Tango Therapeutics in Q4 2024, selling an estimated $5.78M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $9.36B portfolio in Q4 2024.
  • Baker Bros. Advisors opened 8 new positions and closed 7 in Q4 2024.
  • Baker Bros. Advisors's portfolio value fell 3% quarter-over-quarter to $9.36B.

Based on Baker Bros. Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.